by Communication Team | Jan 21, 2021 | ODYSSEY, Publication
On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close...
by Communication Team | Dec 21, 2020 | ODYSSEY
With the world engulfed by the COVID-19 pandemic, you may not have heard about some of the breakthroughs that the scientific community has made in the treatment of paediatric HIV. One such breakthrough is the development of dispersible dolutegravir. Find more on...
by Communication Team | Nov 19, 2020 | ODYSSEY
On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision...
by Communication Team | Aug 6, 2020 | ODYSSEY
Results from a sub-study of the ODYSSEY trial, published in The Lancet HIV journal, show that children over 20kg in weight can safely take adult doses (50mg) of the anti-HIV drug dolutegravir. With over half of children living with HIV globally weighing at over 20kg,...
by Communication Team | Aug 6, 2020 | Publication
Authors: Bollen PDJ, Moore C, Mujuru H, et al. The ODYSSEY Trial TeamPublished in: LANCET HIV. 2020;8:e533-e544 Download
Recent Comments